ArticleJournal of diabetes science and technology2013
DiAs user interface: a patient-centric interface for mobile artificial pancreas systems.
Article in Journal of diabetes science and technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Effect of Afrezza on Glucose Dynamics During HCL Treatment.Diabetes care · 2020Trial
- Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial.Diabetes care · 2020Trial
- Randomized Controlled Trial of Mobile Closed-Loop Control.Diabetes care · 2020Trial
- Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial.The Lancet. Digital health · 2020Trial
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.The New England journal of medicine · 2019Trial
- First Look at Control-IQ: A New-Generation Automated Insulin Delivery System.Diabetes care · 2018Trial
- Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting.Diabetes technology & therapeutics · 2018Trial
- Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin ADiabetes care · 2017Trial
- Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study.Diabetes care · 2017Trial
- Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2017Trial
- Closed-Loop Control Without Meal Announcement in Type 1 Diabetes.Diabetes technology & therapeutics · 2017Trial
- Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial.Diabetes care · 2017Trial
- Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control.Diabetes technology & therapeutics · 2017Trial
- Multinational Home Use of Closed-Loop Control Is Safe and Effective.Diabetes care · 2016Trial
- Multinight "bedside" closed-loop control for patients with type 1 diabetes.Diabetes technology & therapeutics · 2015Trial
- Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas.Diabetes care · 2014Trial
- Early Stages of Automated Insulin Delivery.Journal of diabetes science and technology · 2025Review
- Artificial Pancreas: The First 20 Years.Journal of diabetes science and technology · 2025Article
- Early Stages of Automated Insulin Delivery.Diabetes technology & therapeutics · 2025Review
- Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent in-hospital studies of artificial pancreas (AP) systems have shown promising results in improving glycemic control in patients with type 1 diabetes mellitus. The next logical step in AP development is to conduct transitional outpatient clinical trials with a mobile system that is controlled by the patient. In this article, we present the user interface (UI) of the Diabetes Assistant (DiAs), an experimental smartphone-based mobile AP system, and describe the reactions of a round of focus groups to the UI. This work is an initial inquiry involving a relatively small number of potential users, many of whom had never seen an AP system before, and the results should be understood in that light.
methodsWe began by considering how the UI of an AP system could be designed to make use of the familiar touch-based graphical UI of a consumer smartphone. After developing a working prototype UI, we enlisted a human factors specialist to perform a heuristic expert analysis. Next we conducted a formative evaluation of the UI through a series of three focus groups with N = 13 potential end users as participants. The UI was modified based upon the results of these studies, and the resulting DiAs system was used in transitional outpatient AP studies of adults in the United States and Europe.
resultsThe DiAs UI was modified based on focus group feedback from potential users. The DiAs was subsequently used in JDRF- and AP@Home-sponsored transitional outpatient AP studies in the United States and Europe by 40 subjects for 2400 h with no adverse events.
conclusionsAdult patients with type 1 diabetes mellitus are able to control an AP system successfully using a patient-centric UI on a commercial smartphone in a transitional outpatient environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.